Abstract
A novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist that has recently been approved in several countries for the treatment of type 2 diabetes (T2D) and results in substantial HbA1c reductions and weight loss. The current study aimed to quantify the preferences of people with T2D for the treatment features of this new medication compared with another available product.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
